Morning Research on Gilead Sciences, Halozyme Therapeutics, InterMune, and Seattle Genetics

  Morning Research on Gilead Sciences, Halozyme Therapeutics, InterMune, and
                               Seattle Genetics

PR Newswire

LONDON, March 25, 2013

LONDON, March 25, 2013 /PRNewswire/ --

The biotechnology sector is adapting to the changing market dynamics. In the
last one year, the industry has seen increasing generic competition following
the expiration of patents on several blockbuster drugs. Meanwhile, President
Obama's Affordable Care Act (ACA), which was upheld by the Supreme Court last
year, is expected to result in rising costs for biotechnology companies.
However, biotechnology companies such as Gilead Sciences Inc. (NASDAQ: GILD),
Halozyme Therapeutics Inc. (NASDAQ: HALO), InterMune Inc. (NASDAQ: ITMN), and
Seattle Genetics Inc. (NASDAQ: SGEN) will be hoping to benefit from ACA in the
long-term as the healthcare reform would lead to an increase in the number of
insured individuals. On Friday, biotechnology stocks tracked gains in the
broad market, which rose sharply as concerns over Cyprus's bailout eased a
little. StockCall has posted free technical research reports on GILD, HALO,
ITMN, and SGEN and these can be accessed by signing up at

http://www.stockcall.com/analysis

Shares of Gilead Sciences Inc. rose sharply in trading on Friday. The stock
rose to an intra-day high of $45.56 before paring some of the gains to finish
the day 2.18% higher at $45.51 on volume of 8.29 million. Gilead Sciences
Inc.'s shares are currently hovering around their 52-week high of $46.37. The
stock has had an excellent run so far this year, gaining nearly 24%. The
company's shares have seen a series of highs since the start of this year,
which is a bullish signal. Download the free report on GILD upon registration
at

http://www.StockCall.com/GILD032513.pdf

Halozume Therapeutics Inc. shares were amongst the biggest gainers in the
biotechnology sector on Friday, closing 30.98% higher at $6.90 on above
average volume of 7.75 million. The stock touched an intra-day high of $6.98.
Halozyme Therapeutics shares crossed their 50-day and 200-day moving averages
in trading on Friday, which is a bullish signal. The stock is now trading
close to $7 resistance level. The stock's MACD has also crossed above the
signal line, which is another strong bullish signal. HALO technical report can
be accessed for free by signing up at

http://www.StockCall.com/HALO032513.pdf

InterMune Inc.'s shares edged higher in trading on Friday, extending their
gains from the previous trading sessions. The stock finished 2.67% higher at
$9.61 on above average volume of 1.79 million, taking its gains in the last
three trading sessions to nearly 10.50%. Despite the recent gains, InterMune's
shares are down nearly 1% for the year. In the last one year, the stock has
fallen more than 36.50%. The company's shares crossed their 50-day and 200-day
moving averages as a result of the rally last week, which is a bullish signal.
The upbeat trend is further confirmed by the stock's MACD chart. The free
report on ITMN can be downloaded by signing up now at

http://www.StockCall.com/ITMN032513.pdf

Another major gainer in the biotech sector on Friday was Seattle Genetics Inc.
Shares of the Bothell, Washington-based company rose 4.14% to finish at $36.22
on above average volume of 1.03 million. The stock touched a 52-week high of
$36.35 earlier in the day. Seattle Genetics Inc.'s shares have seen a series
of highs over the last one month, which is a strong bullish signal. The upbeat
trend is further confirmed by recent volume activity and the stock's MACD
chart. Year-to-date, the company's shares have gained more than 56%. Free
report on SGEN can be accessed by registering at

http://www.StockCall.com/SGEN032513.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)